Abstract: A method of assembling a package having an exposed die comprising the following steps. A die attached to a substrate by connectors is provided. The die having a backside. Encapsulate is formed around the die and over the backside of the die to form an encapsulated package. The encapsulate overlying the backside of the die and a portion of the backside of the die are removed using a backside exposure process to complete the assembled package having the die exposed.

Abstract: A semiconductor chip packaging structure is described. The structure comprising of a semiconductor chip interconnected to a recessed lead frame and the resultant assembly encapsulated in a molding compound. The final product is a reverse mounted semiconductor chip in a leadless quad flat pack configuration. A second embodiment allows for the semiconductor chip backside to be exposed for thermal enhancements. Manufacturing methods are also described for the two embodiments disclosed.

Abstract: A chip level package utilizing a CGA is described. A semiconductor chip with pillars is molded in an encapsulant. Solder balls are added and connected to the chip pillars. The final package does not require a first level substrate or interposer and is able to be assembled to the next level as is.

Abstract: A method and structure for controlling solder spread in a predefined/designed area during flip chip assembly build is disclosed. Using conventional processes used in the art blind holes or dimples are incorporated onto the lead frame which then act as containers or wells trapping the solder and thereby preventing it from spreading wider.

Abstract: A method of assembling a package having an exposed die comprising the following steps. A die attached to a substrate by connectors is provided. The die having a backside. Encapsulate is formed around the die and over the backside of the die to form an encapsulated package. The encapsulate overlying the backside of the die and a portion of the backside of the die are removed using a backside exposure process to complete the assembled package having the die exposed.

Abstract: A chip level package utilizing a CGA is described. A semiconductor chip with pillars is molded in an encapsulant. Solder balls are added and connected to the chip pillars. The final package does not require a first level substrate or interposer and is able to be assembled to the next level as is. An additional embodiment describes the addition of a thermal heat sink to the packaged chip.

Abstract: A chip level package utilizing a CGA is described. A semiconductor chip with pillars is molded in an encapsulant. Solder balls are added and connected to the chip pillars. The final package does not require a first level substrate or interposer and is able to be assembled to the next level as is.

Abstract: Antitumor compositions are disclosed, as well as methods of preparing the compositions and methods of using them to inhibit tumor growth in mammals. The invention can take advantage of intraliposomal conversion of a platinum complex having the formula where R1 is diaminocycloalkyl, and R2 and R3 each have the formula where R4, R5, and R6 are each independently hydrocarbon moieties having from 1 to about 10 carbon atoms, into a complex having the formula R1—Pt—X2  (II) where X is halogen.

Abstract: The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-based DNA alkylators.

Abstract: The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4′ of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the preparation of anthracycline antibiotics. These anthracycline analogs show high cytotoxicity in vitro against several tumor cell lines.

Abstract: A method of evaluating the chemosensitivity of a tumor to an anti-tumor agent in vivo is provided. The method comprises extracting a portion of a tumor from a human host and inserting the portion of the tumor into an immunodeficient mouse. The tumor portion is permitted to grow to a minimum preselected size to form a test tumor. An amount of an anti-tumor agent is administered to the immunodeficient mouse sufficient to determine whether the anti-tumor agent is effective in treating the test tumor. The anti-tumor activity of the anti-tumor agent on the test tumor is assessed.

Abstract: A method of treating bronchoalveolar carcinoma, carcinomatosis with lymphangitic spread or primary and metastatic lung cancers by administering one or more bioactive agents by inhalation of a lipid composition. The one or more bioactive agents preferably comprise cisplatin, carboplatin or a taxane.

Abstract: The present invention is directed towards a surgical system and method of use for treating and removing unwanted tissue, preferably from an organ or other internal part of a patient. The system includes a cryosurgical component for first freezing the unwanted living tissue by forming an ice mass which completely encompasses the unwanted living tissue and means for treating the cryogenically-treated tissue and then removing the tissue while it remains in a frozen state. In one embodiment, an ultrasonic device is used to ultrasonically vibrate the cryogenically-treated tissue to break apart the frozen tissue and the frozen broken-up pieces of tissue are removed using a technique, such as an aspiration process.

Abstract: The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-based DNA alkylators.

Abstract: The use of non-viral delivery of therapeutically effective compositions through aerosol for therapy or research purpose has been limited by the low efficiency mainly caused by an inefficient delivery system and destruction of formulation (gene and/or delivery system) by aerosol shearing power. This invention develops formulations that are established polymer combination formulations. The formulations are highly efficient in delivering genes in vivo through aerosol and are able to protect the delivered gene from the destruction by aerosol shearing power.

Abstract: The present invention discloses new and novel substituted anthracyclines with modified alkyl-aromatic ring substitutions on the C-3′ of the sugar moiety or modified or unmodified alkyl-aromatic ring substitutions at the C-4′ of the sugar moiety. It also discloses novel methods for the preparation of sugar substrates and methods for the preparation of anthracycline antibiotics. These anthracycline analogs show high cytotoxicity in vitro against several tumor cell lines.

Abstract: The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moieties. These congeners show high activity in vitro against several tumor cell lines. The invention also describes anthracycline-based DNA alkylators.

Abstract: A sepsis-avoiding and hydrostatic-neutral method of administering platinum therapeutic agents into a body cavity of a subject by means of introduction through a hydrostatic-tight indwelling catheter.

Abstract: The present invention is directed towards a surgical system and method of use for treating and removing unwanted tissue, preferably from an organ or other internal part of a patient. The system includes a cryosurgical component for first freezing the unwanted living tissue by forming an ice mass which completely encompasses the unwanted living tissue and means for treating the cryogenically-treated tissue and then removing the tissue while it remains in a frozen state. In one embodiment, an ultrasonic device is used to ultrasonically vibrate the cryogenically-treated tissue to break apart the frozen tissue and the frozen broken-up pieces of tissue are removed using a technique, such as an aspiration process.

Abstract: A method of evaluating the chemosensitivity of a tumor to an anti-tumor agent in vivo is provided. The method comprises extracting a portion of a tumor from a human host and inserting the portion of the tumor into an immunodeficient mouse. The tumor portion is permitted to grow to a minimum preselected size to form a test tumor. An amount of an anti-tumor agent is administered to the immunodeficient mouse sufficient to determine whether the anti-tumor agent is effective in treating the test tumor. The anti-tumor activity of the anti-tumor agent on the test tumor is assessed.